Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QBMXO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Blinatumomab-Compound 59
|
|||||
| Synonyms |
Blinatumomab Compound 59
Click to Show/Hide
|
|||||
| Organization |
Rongchang Pharmaceuticals Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Acute lymphoblastic leukemia [ICD11:2B33]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3-3.5
|
|||||
| Antibody Name |
Blinatumomab
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19); T-cell surface glycoprotein CD3 delta chain (CD3D)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Blinatumomab-Compound 59 linker
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.